AI assistant
Sending…
Adaptimmune Therapeutics PLC — Director's Dealing 2019
Oct 2, 2019
34721_dirs_2019-10-01_0b40e96c-922b-4755-955f-6d8c5f9b56d8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-10-01
Reporting Person: Garone Michael (Interim CFO)
More from Adaptimmune Therapeutics PLC
Major Shareholding Notification
2026
Feb 17
Regulatory Filings
2025
Nov 17
Major Shareholding Notification
2025
Nov 14
Regulatory Filings
2025
Nov 13
Regulatory Filings
2025
Nov 13
Regulatory Filings
2025
Oct 28
Regulatory Filings
2025
Oct 28
Regulatory Filings
2025
Oct 28
Regulatory Filings
2025
Oct 28
Delisting Announcement
2025
Oct 28